Abstracts tagged "registry"

Abstract Number: 1999 • ACR Convergence 2022
Patient-Reported Outcomes in Rheumatoid Arthritis Correlate with Clinical Disease Activity Index Response in the Study to Accelerate Information of Molecular Signatures (AIMS)
Vibeke Strand¹, Emelly Rusli², Lixia Zhang², Christina Le-Short², Alix Arnaud², Johanna Withers³ and Sam Asgarian², ¹Stanford University School of Medicine, Stanford, CA, ²Scipher Medicine Corporation, Waltham, MA, ³Scipher Medicine Corportaion, Waltham, MA
Background/Purpose: Rheumatoid arthritis (RA) treatment response is typically defined using clinician-reported scores and patient global assessments of disease activity (PtGA), but patients may have a…
Abstract Number: 0950 • ACR Convergence 2022
Obstetric Outcomes in Women with Rheumatic Disease and COVID-19 in the Context of Vaccination Status: Data from the COVID-19 Global Rheumatology Alliance Registry
Sinead Maguire¹, Samar Al emadi², Paul Alba³, Mathia C Aguiar⁴, Talal Al Lawati⁵, Gelsomina Alle⁶, Bonnie Bermas⁷, Suleman Bhana⁸, Branimir Anic⁹, Inita Bulina¹⁰, Megan Clowse¹¹, Adriana Karina Cogo¹², Iris Colunga¹³, Claire Cook¹⁴, KAREN JOYCE CORTEZ¹⁵, Kathryn Dao¹⁶, Milena Gianfrancesco¹⁷, Monique Gore-Massy¹⁸, Laure Gossec¹⁹, Rebecca Grainger²⁰, Jonathan Hausmann²¹, Tiffany YT Hsu²², Kimme Hyrich²³, Carolina Isnardi²⁴, Yumeko Kawano²², Rachael Kilding²⁵, Daria A Kusevich²⁶, Saskia Lawson-Tovey²⁷, Jean Liew²⁸, Eoghan McCarthy²⁹, Anna Montgomery³⁰, Sebastian Moyano³, Noreen Nasir³¹, IVAN PADJEN³², Charalampos Papagoras³³, Naomi Patel³⁴, MARIANA PERA³⁵, Cecilia Pisoni³⁶, Guillermo Pons-Estel³⁷, Antonio Lorenzo Quiambao³⁸, Rosana Quintana³⁹, Eric Ruderman⁴⁰, Sebastian Sattui⁴¹, Veronica Savio⁴², Savino Sciascia⁴³, Marieta Sencarova⁴⁴, Rosa Serrano-Morales⁴⁵, Faizah Siddique⁴⁶, Emily Sirotich⁴⁷, Jeffrey Sparks⁴⁸, Anja Strangfeld⁴⁹, Paul Sufka⁵⁰, Helen Tanner⁵¹, Yohana Tissera⁵², Zachary Wallace¹⁴, Marina Werner⁵³, Leanna Wise⁵⁴, Angus Worthing⁵⁵, JoAnn Zell⁵⁶, Julija Zepa¹⁰, Pedro Machado⁵⁷, Jinoos Yazdany¹⁷, Philip Robinson⁵¹ and Richard Conway¹,¹St James' Hospital, Dublin, Ireland, ²Hamad Medical Corporation, Doha, Qatar, ³Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital General Agustin O`Horan, Merida, Mexico, ⁵Sultan Qaboos University Hospital, Muscat, Oman, ⁶Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷UT Southwestern, Dallas, TX, ⁸Crystal Run Healthcare, Middletown, NY, ⁹Clinical Hospital Centre Zagreb, School of Medicine, University of Zagreb, Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Zagreb, Croatia, ¹⁰Center of Rheumatology, Paul Stradins Clinical University hospital, Riga, Latvia, ¹¹Duke University, Durham, NC, ¹²Hospital Interzonal Luis Guemes, Haedo and Hospital San Juan de Dios, Castelar, Buenos Aires, Argentina, ¹³Hospital Universitario UANL, Monterrey, Mexico, ¹⁴Massachusetts General Hospital, Boston, MA, ¹⁵Baguio General Hospital Medical Center, Baguio, Philippines, ¹⁶UT Southwestern Medical Center, Dallas, TX, ¹⁷University of California San Francisco, San Francisco, CA, ¹⁸Covid-19 GRA, West Orange, NJ, ¹⁹Sorbonne Université, Paris, France, ²⁰University of Otago, Wellington, New Zealand, ²¹Division of Immunology, Boston Children's Hospital, Boston, MA, ²²Brigham and Women's Hospital, Boston, MA, ²³The University of Manchester, Manchester, United Kingdom, ²⁴SAR-COVID Coordinator, Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, ²⁵Sheffield teaching hospitals trust, Sheffield, United Kingdom, ²⁶VA Nasonova Research Institute of Rheumatology, Moscow and Anikina Clinic, Vidnoe, Russia, ²⁷Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, the University of Manchester, Manchester, UK AND National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²⁸Boston University, Boston, MA, ²⁹Beaumont Hospital, Dublin, Ireland, ³⁰University of California, San Francisco, USA; San Francisco VA Medical Center, San Francisco, USA, San Francisco, CA, ³¹Aga Khan University Hospital, Karachi Pakistan, Karachi, Pakistan, ³²University Hospital Center Zagreb, Zagreb, Croatia, ³³First Department of Internal Medicine and Laboratory of Molecular Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece, ³⁴Massachusetts General Hospital, Sale Creek, TN, ³⁵Hospital Ángel C Padilla, San Miguel de Tucumán, Tucuman, Argentina, ³⁶CEMIC- Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina, ³⁷Argentine Society of Rheumatology, Buenos Aires, Argentina, ³⁸East Avenue Medical Center, Quezon City, Philippines, ³⁹Centro Regional de Enfermedades Autoinmunes y Reumáticas. Grupo Oroño (GO CREAR) and Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, ⁴⁰Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴¹University of Pittsburg, Pittsburg, Pennsylvania, USA, PIttsburgh, PA, ⁴²Hospital Córdoba; Consultora Integral de Salud CMP, Cordoba, Argentina, ⁴³University of Turin, Torino, Italy, ⁴⁴Univerzitna nemocnica L Pasteura, Slovakia, Kosice, Slovakia, ⁴⁵Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumáticas del Grupo Oroño, Rosario, Argentina, ⁴⁶Loyola University Medical Center, Elmhurst, IL, ⁴⁷Department of Health Research, Evidence and Impact, McMaster University, Hamilton, ON, Canada, ⁴⁸Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴⁹Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁵⁰HealthPartners, Eagan, MN,⁵¹University of Queensland School of Medicine, Brisbane, Queensland, Australia, ⁵²Internal Medicine Service, Rheumatology Unit, Hospital Córdoba y Sanatorio Parque de Córdoba, Córdoba, Argentina, ⁵³Hospital Nacional de Clínicas, Córdoba, Argentina, ⁵⁴LAC+USC/Keck Medicine of USC, Pasadena, CA, ⁵⁵Arthritis & Rheumatism Associates, PC, Washington, DC, ⁵⁶University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵⁷Centre for Rheumatology & Department of Neuromuscular Diseases, University College London and National Institute for Health Research (NIHR), University College London Hospitals NHS Foundation Trust, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, United Kingdom
Background/Purpose: To describe obstetric outcomes based on COVID-19 vaccination status in women with rheumatic and musculoskeletal diseases (RMDs) who developed COVID-19 during pregnancy.Methods: We extracted…
Abstract Number: 2010 • ACR Convergence 2022
Lowering Expectations: Glucocorticoid Tapering Among Veterans with Rheumatoid Arthritis Achieving Low Disease Activity on Stable Biologic Therapy
Beth Wallace¹, Bryant England², Joshua Baker³, Gary Kunkel⁴, Tawnie Braaten⁵, Jorge Rojas⁶, Alison Petro², Punyasha Roul⁷, Ted Mikuls⁸, Brian Sauer⁹ and Grant Cannon¹⁰, ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Utah, Salt Lake City, UT, ⁵University of Utah Hospitals and Clinics and VA Salt Lake City Health Care System, Salt Lake City, UT, ⁶George E. Wahlen Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁷UNMC, Omaha, NE, ⁸Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁹Salt Lake City VA/University of Utah, Salt Lake City, UT, ¹⁰Retired, Salt Lake City, UT
Background/Purpose: Up to 80% of RA patients use glucocorticoids (GC) at some time in their illness. Current ACR guidelines note that difficulty tapering GC promotes…
Abstract Number: 1023 • ACR Convergence 2022
Are We Treating-to-target in Spondyloarthritis (SpA)? A Cross Sectional Analysis from the Asia Pacific League of Associations for Rheumatology (APLAR) SpA Registry
Isaac Cheng¹, Ying Ying Leung², Ho SO¹, Praveena Chiowchanwisawakit³, Stanley Angkodjojo⁴, Muhammad Saeed⁵, Kichul Shin⁶, Han Joo Baek⁷, Mohit Goyal⁸, Muhammad Haroon⁹, Eman Satti¹⁰, Nallasivan Subramanian¹¹, Fariz Yahya¹², Soosan Soroosh¹³, ASAL ADNAN RIDHA¹⁴, Ho Yin Chung¹⁵, James Cheng-Chung WEI¹⁶, Kishimoto Mitsumasa¹⁷ and Lai-shan Tam¹, ¹The Chinese University of Hong Kong, Hong Kong, China, ²Rheumatology Department, Singapore General Hospital, Singapore, Singapore, ³Mahidol University, Bangkok, Thailand, ⁴Sengkang General Hospital / Singhealth, Singapore, Singapore, ⁵Central Park Medical College, Lahore, Pakistan, ⁶Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea, ⁷Gachon University College of Medicine, Inchon, Republic of Korea, ⁸CARE Pain & Arthritis Centre, Udaipur, India, ⁹Doctor, Tralee, Ireland, ¹⁰Hamad Medical Corporation, Doha, Qatar, ¹¹Velammal Medical College Hospital, Velammal, India, ¹²University of Malaya, Kuala Lumpur, Malaysia, ¹³Army University for Medical School, Tehran, Iran, ¹⁴Baghdad Teaching Hospital, Baghdad, Iraq, ¹⁵Chiron Medical, Hong Kong, Hong Kong, ¹⁶Chung Shan Medical University Hospital, Taichung, Taiwan, ¹⁷Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: Data on the extent to which internationally agreed treat-to-target (T2T) recommendations were applied in clinical practice in patients with SpA across the Asia-Pacific region…
Abstract Number: 2217 • ACR Convergence 2022
Disease Response in Rheumatoid Arthritis Across 4 Biologic Therapies Associates with Improvement in Paraoxonase-1 Activity
Amir Razmjou¹, Jennifer Wang¹, Ani Shahbazian¹, Jeffrey Curtis², Dimitrios Pappas³, Joel Kremer⁴ and Christina Charles-Schoeman⁵, ¹UCLA Medical Center, Los Angeles, CA, ²University of Alabama at Birmingham, Hoover, AL, ³CorEvitas, LLC, Waltham, MA, ⁴The Corrona Research Foundation, Delray Beach, FL, ⁵Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA
Background/Purpose: Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme with paraoxonase, lactonase, and arylesterase activities (1). PON1 is integral to the anti-inflammatory, anti-atherogenic functions of…
Abstract Number: 1053 • ACR Convergence 2022
The Collaborative National Quality and Efficacy Registry for Scleroderma: Association of Resource Utilization and Gastrointestinal Tract Symptoms in Early Disease
Sarah Luebker¹, Tracy Frech¹, Shervin Assassi², Jessica Gordon³, Elana Bernstein⁴, Virginia Steen⁵, Laura Hummers⁶, Ami Shah⁷, Carrie Richardson⁸, Dinesh Khanna⁹, Flavia Castelino¹⁰, Lorinda Chung¹¹, Faye Hant¹², Vicki Shanmugam¹³, John VanBuren¹⁴, Jessica Alvey¹⁴, Monica Harding¹⁴, Luke Evnin¹⁵ and Nora Sandorfi¹⁶, ¹Vanderbilt University Medical Center, Nashville, TN, ²McGovern Medical School, University of Texas, Houston, TX, ³Hospital for Special Surgery, New York, NY, ⁴Columbia University, New York, NY, ⁵Georgetown University School of Medicine, Washington, DC, ⁶Johns Hopkins Univerisity, Baltimore, MD, ⁷Johns Hopkins Rheumatology, Baltimore, MD, ⁸Northwestern University, Chicago, IL, ⁹Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹⁰Massachusetts General Hospital, Boston, MA, ¹¹Stanford University, Stanford, CA, ¹²Medical University of South Carolina, Charleston, SC, ¹³George Washington University, Washington, DC, ¹⁴University of Utah, Salt Lake City, UT, ¹⁵Scleroderma Research Foundation, Brisbane, CA, ¹⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Health costs and resource utilization are important in chronic disease management. Systemic sclerosis (SSc) is a multi-organ system disease with outcomes that are often…
Abstract Number: 2268 • ACR Convergence 2022
Recurrent Thrombosis Risk in Non-anticoagulated Antiphospholipid Syndrome Patients: A Prospective Case-Control Study from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Cecile Yelnik¹, Zeynep Belce Erton², Elodie Drumez³, Dachi Cheildze², Danieli Castro Oliveira de Andrade⁴, Ann E Clarke⁵, Maria G. Tektonidou⁶, Vittorio Pengo⁷, Savino Sciascia⁸, Amaia Ugarte⁹, H Michael Belmont¹⁰, Mª Angeles Aguirre¹¹, Paul fortin¹², maria gerosa¹³, Flavio Victor Signorelli¹⁴, Tatsuya Atsumi¹⁵, Zhouli Zhang¹⁶, Hannah Cohen¹⁷, D. Ware Branch¹⁸, Denis Wahl¹⁹, Laura Andreoli²⁰, Esther Rodriguez Almaraz²¹, Michelle Petri²², Ricard Cervera²³, Yu Zuo²⁴, Bahar Artim-Esen²⁵, Guillermo Pons-Estel²⁶, Rohan Willis²⁷, Maria Laura Bertolaccini²⁸, Robert Roubey²⁹, Doruk Erkan² and on behalf of APS ACTION On Behalf Of APS ACTION², ¹Lille University, Lille, France, ²Hospital for Special Surgery, New York, NY, ³Université de Lille, Lille, France, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ⁶National and Kapodistrian University of Athens, Athens, Greece, ⁷Padova University Hospital, Padova, Italy, ⁸University of Turin, Torino, Italy, ⁹BioCruces Bizkaia Health Research Institute, Barakaldo, Spain, ¹⁰NYU School of Medicine, New York, NY, ¹¹Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain, ¹²CHU de Québec, Pavillon CHUL, Québec, Canada, ¹³University of Milan, Milano, Italy, ¹⁴Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁵Hokkaido University, Sapporo, Japan, ¹⁶Peking University First Hospital, Beijing, China, ¹⁷University College London, London, United Kingdom, ¹⁸University of Utah, Salt Lake City, UT, ¹⁹Université de Nancy, Nancy, France, ²⁰Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²¹Hospital Universitario 12 de Octubre, Madrid, Spain, ²²Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ²³Hospital Clínic de Barcelona, Barcelona, Spain, ²⁴University of Michigan, Ann Arbor, MI, ²⁵Istanbul University, Istanbul, Turkey, ²⁶CREAR, Rosario, Argentina, ²⁷University of Texas Medical Branch, Galveston, TX, ²⁸King's College London, London, United Kingdom, ²⁹University of North Carolina, Chapel Hill, NC
Background/Purpose: Long-term anticoagulation is the standard of care for antiphospholipid syndrome (APS) patients with macrovascular thrombosis. However, in daily practice, long-term anticoagulation may not be…
Abstract Number: 1084 • ACR Convergence 2022
Rituximab versus Cyclophosphamide for Induction Therapy in Granulomatosis with Polyangiitis: A Target Trial Emulation Study
Xavier Puéchal¹, Michele Iudici², Elodie Perrodeau³, bernard bonnotte⁴, Francois Lifermann⁵, Thomas Le Gallou⁶, Alexandre Karras⁷, Claire Blanchard-Delaunay⁸, Thomas Quéméneur⁹, Achille Aouba¹⁰, Olivier Aumaître¹¹, Vincent Cottin¹², Mohamed Hamidou¹³, Marc Ruivard¹¹, Pascal Cohen¹, Luc Mouthon¹, Loïc Guillevin¹, Philippe Ravaud³, Raphaël Porcher³ and Benjamin Terrier¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ³Université Paris Cité, Hôtel-Dieu, Paris, France, ⁴Centre Hospitalo-Universitaire de Dijon, Dijon, France, ⁵Dax Hospital, Dax, France, ⁶Rennes Sud University Hospital, Rennes, France, ⁷HEGP, Paris, France, ⁸Niort Hospital, Niort, France, ⁹Valenciennes Hospital, Valenciennes, France, ¹⁰Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, ¹¹Clermont Ferrand University Hospital, Clermont-Ferrand, France, ¹²Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ¹³Nantes University Hospital, Nantes, France
Background/Purpose: Randomized controlled trials showed rituximab (RTX)'s non-inferiority to cyclophosphamide (CYC) for induction therapy of ANCA-associated vasculitis and neither treatment was favoured in granulomatosis with…
Abstract Number: 0192 • ACR Convergence 2021
Influence of Canakinumab Dosing on Efficacy and Safety of Long-term Treatment in Patients with Familial Mediterranean Fever – Interim Analysis of the RELIANCE Registry
Jorg Henes¹, Norbert Blank², Tilmann Kallinich³, Frank Dressler⁴, Gerd Horneff⁵, Ivan Foeldvari⁶, Markus Hufnagel⁷, Birgit Kortus-Goetze⁸, Frank Weller-Heinemann⁹, Florian Meier¹⁰, Julia Weber-Arden¹¹ and Jasmin Kuemmerle-Deschner¹², ¹University Hospital Tuebingen, Tuebingen, Germany, ²Rheumatology, University Hospital Heidelberg, Eppelheim, Germany, ³Charité University Medicine, Nuremberg, Germany, ⁴Division of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany, ⁵Paediatric Rheumatology International Trials Organisation (PRINTO), Sankt Augustin, Germany, ⁶Hamburger Zentrum fuer Kinder- und Jugendrheumatologie, Hamburg, Germany, ⁷Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany, ⁸Division of Nephrology, University of Marburg, Marburg, Germany, ⁹Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, ¹⁰1 Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany 2 Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main, Germany, Frankfurt a.M., Germany, ¹¹Novartis Pharma GmbH, Nuremberg, Germany, ¹²Pediatric Rheumatology and Autoinflammatory Reference Center, University Children's Hospital Tuebingen, Tuebingen, Germany
Background/Purpose: Familial Mediterranean Fever (FMF) is characterized by severe systemic and organ inflammation. Successful treatment with rapid remission of symptoms and normalization of laboratory parameters…
Abstract Number: 0827 • ACR Convergence 2021
Discontinuation Rate of Tofacitinib as Monotherapy Is Similar Compared to Combination Therapy with Methotrexate in Rheumatoid Arthritis Patients: Pooled Data from Two Rheumatoid Arthritis Registries in Canada
Mohammad Movahedi¹, Denis Choquette², Louis Coupal², Angela Cesta³, Xiuying Li³, Edward Keystone⁴ and Claire Bombardier⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ³Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ⁴Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment and is prescribed alone or with methotrexate (MTX). We previously…
Abstract Number: 0237 • ACR Convergence 2021
Self-perceived General Health at Start of Anti-TNF Therapy Predicts Therapeutic Response in Patients with Rheumatoid Arthritis: Analysis from the Czech Biologics Registry ATTRA
Jakub Zavada¹ and Lucie Nekvindova², ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institut biostatistiky a analýz, spin-off společnost Masarykovy univerzity, Brno, Brno, Czech Republic
Background/Purpose: SF-36 and its components, as well as other PROs have been shown to predict various disease outcomes. We hypothesized that positive responses to questions…
Abstract Number: 0844 • ACR Convergence 2021
Switching Biologics and Failure to Attain Remission in the First Year Predicts bDMARD Refractory Disease in Rheumatoid Arthritis: A 15-year Follow up of the Alberta Biologics Pharmacovigilance Cohort
Stephanie Keeling¹, Britney Jones², Jill Hall³, Joanne Homik⁴, Anthony Russell¹, Luck Lukusa⁵, Sasha Bernatsky⁶ and Walter Maksymowych⁷, ¹Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, ²University of Alberta/University of Calgary, Edmonton, AB, Canada, ³Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁶McGill University, Montréal, QC, Canada, ⁷Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada
Background/Purpose: A subset of patients with rheumatoid arthritis (RA) experience refractory disease and do not attain remission imparting worse long-term outcomes. We evaluated RA patients…
Abstract Number: 0245 • ACR Convergence 2021
Long-term Safety and Effectiveness of Abatacept Treatment in Patients with JIA: 5-year Results from the PRCSG/PRINTO JIA Real-World Registry
Hermine Brunner¹, Daniel Lovell², Michael Henrickson¹, Ruy Carrassco³, Kirsten Minden⁴, Lyudmila Grebenkina⁵, James Nocton⁶, Ingrid Louw⁷, Linda Wagner-Weiner⁸, Gabriel Vega Cornejo⁹, Sylvia Kamphuis¹⁰, Vyacheslav Chasnyk¹¹, Heather Walters¹², Simone Appenzeller¹³, Jordi Anton¹⁴, Alyssa Dominique¹⁵, Robert Wong¹⁶, Lixian Dong¹⁵, Tzuyung Douglas Kou¹⁵, Alberto Martini¹⁷ and Nicolino Ruperto¹⁸, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, ³Presbyterian Health Services, Albuquerque, NM, ⁴Charite University Hospital Berlin, Berlin, Germany, ⁵Togliatti City Clinical Hospital №5, Togliatti, Russia, ⁶Medical College of Wisconsin, Milwaukee, WI, ⁷Panorama Medical Centre, Cape Town, South Africa, ⁸University of Chicago (Comer Children's), Chicago, IL, ⁹Crea de Guadalajara/Hospital México Americano, Guadalajara, Mexico, ¹⁰Sophia Children’s Hospital, Erasmus University Medical Center, Rotterdam, Netherlands, ¹¹Saint-Petersburg State Pediatric Medical Academy, Saint Petersburg, Russia, ¹²Cohen Children's Hospital, New York, NY, ¹³Hospital das Clínicas da Universidade Estadual de Campinas, Campinas, Brazil, ¹⁴Hospital Sant Joan de Deu, University of Barcelona, Barcelona, Spain, ¹⁵Bristol Myers Squibb, Princeton, NJ, ¹⁶Bristol Myers Squibb, Basking Ridge, NJ, ¹⁷Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ¹⁸IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy
Background/Purpose: Abatacept (ABA) is well tolerated and effective in patients with JIA.1 The Pediatric Rheumatology Collaborative Study Group (PRCSG)/ Paediatric Rheumatology INternational Trials Organisation (PRINTO)…
Abstract Number: 0853 • ACR Convergence 2021
A Combined Patient Registry and Biobank Laboratory Information System for Prospective Multisite Chronic Rheumatic Disease Research Using REDCap
Craig Willers¹, Tom Lynch¹, Vibhasha Chand², Mohammad Islam³, Marissa Lassere⁴, Helen Keen⁵, Tony Kenna⁶, Susan Lester⁷, Ranjeny Thomas⁸, Premarani Sinnathurai⁹, Mihir Wechalekar¹⁰, Ashley Fletcher¹¹, Daniel Lightowler¹², Sheeraz Mohd¹³, Nishta Ramnoruth¹⁴, Carlee Ruediger¹⁵, Helen Weedon¹⁶ and Lyn March¹⁷, ¹Institute of Bone and Joint Research, Kolling Institute, University of Sydney, St Leonards, Australia, ²Public Health and Preventive Medicine, Monash University, Melbourne, Australia, ³Information and Communications Technology, University of Sydney, Sydney, Australia, ⁴St George Hospital; School of Population Health, University of New South Wales, Carlton, Australia, ⁵University of Western Australia, Daglish, Australia, ⁶Queensland University of Technology, School of Biomedical Sciences, Brisbane, Australia, ⁷Rheumatology Department, The Basil Hetzel Institute, The Queen Elizabeth Hospital, Adelaide, Australia, ⁸University of Queensland, Diamantina Institute, Brisbane, Australia, ⁹Institute of Bone and Joint Research, Kolling Institute, University of Sydney; Department of Rheumatology, Royal North Shore Hospital, Northern Sydney Local Health District, Sydney, Australia, ¹⁰Flinders Medical Centre, Southern Adelaide Local Health Network, Bedford Park, Australia, ¹¹Cabrini Health, Malvern, Australia, ¹²Medical School, University of Western Australia; Rheumatology Department, Fiona Stanley Hospital, Perth, Australia, ¹³Fiona Stanley Hospital, South Metropolitan Health Services, Perth, Australia, ¹⁴Diamantina Institute, University of Queensland, Brisbane, Australia, ¹⁵University of Adelaide; The Queen Elizabeth Hospital, Adelaide, Australia, ¹⁶Flinders University, Bedford Park, Australia, ¹⁷Institute of Bone and Joint Research, Kolling Institute, University of Sydney; Department of Rheumatology, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, Sydney, Australia
Background/Purpose: As we enter the big data revolution, comprehensive informatics solutions are essential to realising precision medicine for rheumatic and other chronic disease patients, especially…
Abstract Number: 0254 • ACR Convergence 2021
Patient and Disease-Level Factors Associated with Sustained Cessation of Medication for Disease Remission in Systemic Juvenile Idiopathic Arthritis
Elaine Flanagan¹, Rosemary Peterson², Susan Shenoi³, Helena Chang⁴, Kelly Wang⁴, Rebecca Trachtman⁴ and Karen Onel⁵, ¹Emory/CHOA, Atlanta, GA, ²Dell Children's Medical Center, Austin, TX, ³Seattle Children's Hospital, Seattle, WA, ⁴Icahn School of Medicine at Mount Sinai, New York, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: The emergence of IL-1 and IL-6 inhibitors (biologics) for the treatment of systemic juvenile idiopathic arthritis (SJIA) has dramatically improved patient outcomes. With higher…

« Previous Page
1
…
7
8
9
10
11
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].